DONNA partner TapImmune announced a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. The primary endpoints are dosing regimens and safety. Secondary endpoints are T-cell specific responses and evaluation of objective responses. TPIV 200 is currently being investigated in another Phase 2 trial at the Mayo Clinic that is expected to start enrollment later this year. GO TEAM GO!